Catalyst Pharmaceuticals, Inc.
CPRX
$24.40
$0.160.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.84% | 1.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.84% | 1.25% | |||
| Cost of Revenue | 10.15% | 1.36% | |||
| Gross Profit | 1.34% | 1.23% | |||
| SG&A Expenses | 12.54% | 3.31% | |||
| Depreciation & Amortization | 1.29% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.52% | 2.32% | |||
| Operating Income | -6.67% | -0.05% | |||
| Income Before Tax | 1.22% | 2.51% | |||
| Income Tax Expenses | 5.21% | 6.21% | |||
| Earnings from Continuing Operations | -0.16% | 1.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.16% | 1.30% | |||
| EBIT | -6.67% | -0.05% | |||
| EBITDA | -5.68% | -0.10% | |||
| EPS Basic | -0.39% | 0.94% | |||
| Normalized Basic EPS | -6.52% | 0.87% | |||
| EPS Diluted | -2.38% | 2.44% | |||
| Normalized Diluted EPS | -6.54% | 1.58% | |||
| Average Basic Shares Outstanding | 0.25% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.26% | -0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||